Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
Genetic Test for Breast Cancer Screening Cost-Effective for Women at Intermediate Risk
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
The American Cancer Society has recommended annual magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in women who have a lifetime risk of breast cancer of approximately 25% to ?50%, as determined by models such as the Gail risk test. A new simulated clinical trial evaluated the cost-effectiveness of using 7 single-nucleotide polymorphisms (7SNPs) in combination with the Gail test to assess the cost-benefit of annual MRI screening in women at risk for breast cancer (Folse HJ, et al.
Cancer Prev Res [Phila]
. 2013;6:1328-1336).
Read Article
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
By
Wayne Kuznar
2018 AONN+ Midyear Conference
,
Economics & Value
February 2014, Vol 5, No 1
New Orleans, LA—Peripheral T-cell lymphoma (PTCL) is associated with high resource utilization rates and high overall costs, according to a multicenter study presented at ASH 2013.
Read Article
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—New research has confirmed that 30-day readmission for reduced-toxicity conditioning allogeneic hematopoietic-cell transplantation (allo-HCT) is linked to greater 100-day posttransplant hospital charges.
Read Article
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—More patients with diffuse large B-cell lymphoma (DLBCL) are receiving rituximab infusions in the hospital setting, incurring greater costs than those receiving infusions in the office or clinic, an examination of medical and pharmacy claims has shown.
Read Article
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—Recipients of allogeneic hematopoietic cell transplant are at high risk for financial burden, according to survey-based data collected by Nandita Khera, MD, MPH, a medical oncologist from the Blood and Marrow Transplant Program, Mayo Clinic Arizona, Phoenix, and colleagues.
Read Article
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
New Orleans, LA—The use of decitabine (Dacogen) is more cost-effective than conventional induction therapy for patients aged >60 years with acute myeloid leukemia (AML), according to data from a recent economic analysis.
Read Article
Higher Copays for Imatinib Lead to Medication Nonadherence in Patients with CML
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>Patients with chronic myeloid leukemia (CML) and high out-of-pocket (OOP) costs for treating their disease have a 70% chance of discontinuing treatment and a 42% chance of nonadherence to treatment compared with patients with lesser copays. These conclusions, which were recently published online (Dusetzina SB, et al.
J Clin Oncol
.
Read Article
ASCO Proposes New Reimbursement Model by Medicare for Cancer Care
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
The American Society of Clinical Oncology (ASCO) has proposed a radical new model for the reimbursement of oncology services under Medicare, with the new paradigm consisting of incentives for oncologists to emphasize quality rather than quantity of care as the greater good to the bottom line.
Read Article
Can FDA Drug Approval Keep Pace with Translational Research?
By
Audrey Andrews
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
With the development of targeted therapies, there has been a clear evolution in the pathway to the approval of drugs by the US Food and Drug Administration (FDA), and a rapid approval of a drug after phase 1 clinical trials, which show definitive proof of activity and safety, and “breakthrough” designation, are now possible.
Read Article
PET Use for NSCLC Management Has Altered Resource Utilization, Increased Cost
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Atlanta, GA—The adoption of positron emission tomography (PET) imaging for the management of patients with non–small-cell lung cancer (NSCLC) has had a mixed impact on clinical and economic outcomes, according to findings from a large retrospective cohort study.
Read Article
Page 12 of 18
7
8
9
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma